1
|
Ghelfi AM, Garavelli F, Meres B, Dipaolo FR, Lassus MN, Pahud AL, Vazquez M, Kilstein JG, Mamprin D'Andrea RF. [Nephrotic syndrome due to preeclampsia: Presentation, management and clinical evolution observed in 5 years experience]. HIPERTENSION Y RIESGO VASCULAR 2023; 40:16-24. [PMID: 35835705 DOI: 10.1016/j.hipert.2022.05.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2022] [Revised: 05/19/2022] [Accepted: 05/29/2022] [Indexed: 10/17/2022]
Abstract
INTRODUCTION Nephrotic syndrome (NS) is rare during pregnancy. The main cause is severe pre-eclampsia (PR). Our aim was to describe the clinical presentation, analytical features, medical management, and progress of women with NS due to PE. MATERIALS AND METHODS A descriptive, retrospective study, conducted from 01/01/2017 to 01/01/2022 (5years). Women with a gestational age (GA) ≥20weeks were included in the study, hospitalised due to hypertensive disorders in pregnancy (HDP), with no evidence of kidney damage prior to gestation. RESULTS Of the 652 HDP, 452 PE and 21 NS were identified. Maternal age was 25±5.7 years, GA at diagnosis was 33.1±5.1 weeks. All the women had facial and peripheral oedema: 5 pleural effusion, 3 pericardial effusion, and 2 anasarca. Their p24 was 6.17±2.34grams (3.10-10.8), serum albumin 2.5±0.27g/dL (2.10-2.90), and serum cholesterol 281.4±21.7mg/dL (251-316). Thirteen developed maternal complications: acute kidney damage, pulmonary oedema, dilated cardiomyopathy, eclampsia, and HELLP syndrome. They all remained hypertensive postpartum, and required a combination of two to three antihypertensive drugs. They all received statins postpartum, and angiotensin converting enzyme (ACE) inhibitors to manage proteinuria. None developed hyperkalaemia or creatinine elevation. Hospital stay was 10.4±3.7days. All nephrotic range proteinuria parameters reversed prior to discharge. No deaths were recorded. CONCLUSION Presentation ranged from peripheral oedema to serous involvement. Severity of proteinuria varied. Use of ACE inhibitors did not precipitate hyperkalaemia or kidney failure. Maternal complications were frequent, but no deaths were recorded.
Collapse
Affiliation(s)
- A M Ghelfi
- Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina; Unidad de Hipertensión Arterial y Riesgo Cardiovascular, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina.
| | - F Garavelli
- Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina; Unidad de Hipertensión Arterial y Riesgo Cardiovascular, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - B Meres
- Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - F R Dipaolo
- Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - M N Lassus
- Unidad de Hipertensión Arterial y Riesgo Cardiovascular, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina; Servicio de Tocoginecología, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - A L Pahud
- Servicio de Tocoginecología, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - M Vazquez
- Servicio de Tocoginecología, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - J G Kilstein
- Servicio de Clínica Médica, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| | - R F Mamprin D'Andrea
- Unidad de Hipertensión Arterial y Riesgo Cardiovascular, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina; Servicio de Tocoginecología, Hospital Escuela Eva Perón, Granadero Baigorria, Santa Fe, Argentina
| |
Collapse
|
2
|
[Pharmacological treatment of non-severe hypertension during pregnancy, postpartum and breastfeeding]. HIPERTENSION Y RIESGO VASCULAR 2021; 38:133-147. [PMID: 33632659 DOI: 10.1016/j.hipert.2021.01.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 01/25/2021] [Accepted: 01/27/2021] [Indexed: 11/23/2022]
Abstract
Hypertension (HTN) in pregnancy is defined as systolic blood pressure ≥ 140 and/or diastolic blood pressure ≥ 90 mmHg. Based on the values, it is classified as non-severe (< 160/110 mmHg) and severe (≥ 160/110 mmHg). Before starting treatment in non-severe HTN, white- coat HTN should be ruled out. If outpatient management is possible, pharmacological initiation is suggested with sustained high values, avoiding < 120/80 mmHg. Safe drugs during pregnancy are methyldopa, labetalol, and nifedipine-retard. The use of nifedipine-XL or amlodipine can be considered with a lower level of evidence of safety. Diuretics, atenolol, and other beta-blockers for antihypertensive purposes is not recommended in this period. Renin-angiotensin-aldosterone system inhibitors are strictly contraindicated. In postpartum and breastfeeding, the same therapeutic regimen used during pregnancy can be maintained, trying early withdrawal of methyldopa. During puerperium, amlodipine and enalapril are safe, with minimal excretion in breast milk.
Collapse
|